drugset / Trial / NCT03075878
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
Non-randomizedSequentialOpen-labelTreatment
Summary
This main study objective was to evaluate the safety and tolerability of intravenous (IV) SYNT001 (ALXN1830) in participants with WAIHA.
Timeline
- Start
- 2018-01-10
- Primary completion
- 2019-04-15
- Completion
- 2019-08-06
Outcome
Outcome not reported
Stopped: “Focus resources on a planned phase 2/3 study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORILANOLIMAB | Monoclonal antibody | — | Intravenous |